A combined strategy of intracoronary thrombolysis, abciximab, and PTCA successfully achieved reperfusion in a patient with multiple coronary thromboemboli.
No takes yet. Share an insight, caveat, or question.
Suggests combined intracoronary thrombolysis, abciximab, and PTCA as a possible bailout in thromboembolic occlusion; hypothesis-generating and requires prospective trials.
Mart� et al. (2000) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: